Key Concepts

India is the world's third-largest pharmaceutical industry by volume and the largest supplier of generic medicines globally, earning the epithet "pharmacy of the world." India supplies ~20% of global generic medicines by volume and provides ~60% of global vaccine demand. However, this export strength masks a structural vulnerability — heavy import dependence on China for Active Pharmaceutical Ingredients (APIs).

India's Pharma Sector: Scale and Significance

  • Market size: India's domestic pharma market: approximately USD 57.6 billion (2025, Mordor Intelligence); estimated USD 60.3 billion in 2026; total industry (domestic + exports) ~USD 90+ billion; projected to reach USD 130 billion by 2030
  • Exports: India exports to over 200 countries; pharma exports reached $30.47 billion in FY 2024-25 and crossed $31 billion in FY 2025-26 (Pharmexcil); Pharmexcil target: $65 billion by 2030
  • Generics dominance: India is the largest provider of generic drugs to the US (accounts for approximately 40–50% of US generic prescriptions by volume, up from ~21% in 2013 to ~42% in 2022; industry estimates suggest over 95% of Indian pharma exports to the US are generic drugs)
  • Vaccine supply: Serum Institute of India is the world's largest vaccine manufacturer by volume

The API Problem: China Dependence

Active Pharmaceutical Ingredients (APIs) are the biologically active components in medicines. Bulk drugs (another term) form the raw material for finished formulations.

India imported APIs and bulk drugs worth approximately Rs 377 billion in 2023–24, of which China accounted for approximately 70% of imports (in specific antibiotic categories, the share is as high as 87%). China's share in India's API imports rose from ~70% in 2019 to ~72% in 2022, and remains critically high despite policy interventions.

This dependence creates strategic vulnerability — during COVID-19 supply disruptions, Indian manufacturers faced shortage of key antibiotic and paracetamol APIs sourced from China.

Production Linked Incentive (PLI) Scheme for Pharma

The Government launched two pharma-related PLI schemes:

PLI for Bulk Drugs (APIs)

  • Outlay: Rs 6,940 crore
  • Targets 41 critical APIs (antibiotics, anti-retrovirals, vitamins) where India is >80% import dependent
  • Investment achieved: Rs 4,570 crore by March 2025 (exceeding initial committed targets)
  • Production capacity created for 25 targeted products; cumulative sales Rs 1,817 crore
  • Bulk Drug Parks (3 approved: Himachal Pradesh, Andhra Pradesh, Gujarat) with shared infrastructure

PLI for Finished Dosage Formulations (FDF)

  • Targets high-value niche drugs (biopharmaceuticals, complex generics, patented drugs going off-patent)
  • Outlay: Rs 15,000 crore over 6 years

Drug Regulation Framework

Drugs and Cosmetics Act, 1940

  • Principal legislation governing manufacture, distribution, sale, and import of drugs and cosmetics
  • Amended multiple times; sets standards for drug quality and safety
  • Schedule H, H1, X: prescription drug schedules
  • Schedule M: Good Manufacturing Practices (GMP) for drug manufacturing

Central Drugs Standard Control Organisation (CDSCO)

  • Under Ministry of Health and Family Welfare
  • India's national regulatory authority for drugs, cosmetics, diagnostics, devices
  • Headed by the Drugs Controller General of India (DCGI)
  • Approves new drugs for clinical trials and market authorisation (equivalent to US FDA)
  • Coordinates with State Drug Controllers for licensing manufacturing units

National Pharmaceutical Pricing Authority (NPPA)

  • Under Ministry of Chemicals and Fertilizers
  • Fixes prices of essential medicines under the National List of Essential Medicines (NLEM)
  • Regulates under Drug Prices Control Order (DPCO), 2013
  • Controls prices of ~900+ formulations (NLEM 2022 has 384 drugs)
  • Uses market-based pricing for NLEM drugs (ceiling = average of top three brands)

TRIPS Flexibilities and Compulsory Licensing

India's Patent Law and TRIPS

India's Patents Act, 1970 (amended 2005 to comply with TRIPS) has two key provisions that balance innovation and public health:

  • Section 3(d): Prevents "evergreening" — prohibits patents on new forms (salts, esters) of known substances unless they show significantly enhanced efficacy. Used to reject Novartis's application for Glivec (Gleevec) in the landmark Novartis AG v. Union of India (2013) Supreme Court judgment.
  • Section 84: Allows compulsory licensing if a drug is not available at a reasonably affordable price, or not adequately worked in India.

Natco Pharma vs Bayer: India's First Compulsory License (2012)

  • Date: Granted on 9 March 2012 (published 12 March 2012) by the Controller General of Patents
  • Drug: Sorafenib Tosylate (brand name: Nexavar) — used for kidney and liver cancer
  • Issue: Bayer's price was ~Rs 2.8 lakh per month; Natco offered it at Rs 8,880 per month (~3% of Bayer's price)
  • Royalty: Natco paid 6% of net sales to Bayer
  • Significance: India's first-ever compulsory license; demonstrated that TRIPS flexibilities (Doha Declaration) can be used for public health

Jan Aushadhi Scheme

Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP):

  • Launched in 2008; rebranded and expanded in 2016
  • Provides quality generic medicines at 50–90% cheaper than branded alternatives
  • Administered by Bureau of Pharma PSUs of India (BPPI) under Ministry of Chemicals and Fertilizers
  • Stores: 16,912 Jan Aushadhi Kendras (JAKs) across India (as of June 2025)
  • Target: 25,000 stores by March 2027
  • Product range: 2,110 medicines + 315 surgical consumables (as of 2025)
  • Savings to citizens: ~Rs 30,000 crore cumulative (2014–2024); Rs 7,350 crore in FY24 alone

Cross-paper relevance

  • GS3 — Science-Technology (primary) — Pharma industry: $30.47B exports FY25, Jan Aushadhi Kendras (16,912 stores), UCPMP 2024, CDSCO regulation, PLI for pharmaceuticals
  • GS3 — Economy — Industrial policy: PLI Scheme for pharma, bulk drug parks, API (active pharmaceutical ingredient) self-reliance, Make in India in healthcare
  • GS2 — Governance/social justice dimension: DPCO price control, essential medicines access, Pradhan Mantri Bhartiya Janaushadhi Pariyojana equity
  • Essay — Recurring theme: "India's pharma sector: from copyist to innovator" (2022); "Access to medicines as a human right" (2021)

Recent Developments (2024–2026)

India's Pharma Exports — $30.47 Billion FY25, $31 Billion FY26

India's pharmaceutical exports grew 9.4% to $30.47 billion in FY 2024–25 and crossed $31 billion in FY 2025–26 (₹2.74 lakh crore, per Pharmexcil/DrugsControl.org). India is the world's third-largest pharmaceutical producer by volume (14th by value) and the largest supplier of generic medicines globally — contributing approximately 20% of global generic drug volumes and over 50% of global vaccine demand (measured in doses). Export destinations span 200+ countries, with the USA (approximately 34–35%), Europe (19%), and Africa among the significant markets. However, the US market contracted by ~11.5% in FY26, introducing headwinds; diversification to emerging markets has partially offset this.

The PLI (Production-Linked Incentive) Scheme for Pharmaceuticals (₹15,000 crore) specifically targets API (Active Pharmaceutical Ingredient) manufacturing — India imports approximately 65–70% of APIs from China, creating strategic vulnerability. PLI pharma has supported 72 approved projects for critical APIs, fermentation-based products, and biopharmaceuticals. India's API production for paracetamol, penicillin, and vitamins has increased, reducing Chinese dependence. Pharmexcil's target: $65 billion in pharma exports by 2030.

UPSC angle: India's pharma export value ($30.47 billion FY25, $31 billion FY26), global rank, US market share (~40–50% of US generic prescriptions), API-China dependence (65–70%), PLI pharma scheme, $65 billion 2030 target, and market diversification challenge are Prelims and Mains facts.

Drugs (Amendment) Bill and Pharmaceutical Regulation 2024

The Ministry of Health and Family Welfare circulated the draft Drugs, Cosmetics and Medical Devices Bill in 2024, aimed at replacing the outdated Drugs and Cosmetics Act 1940. Key proposed changes include: a separate regulatory framework for medical devices (currently under drugs regulation); faster approval pathways for innovative drugs and biosimilars; strengthened pharmacovigilance (post-market surveillance); and enhanced penalties for spurious/adulterated drugs.

CDSCO (Central Drugs Standard Control Organisation) received enhanced capacity funding in 2024 to accelerate new drug approvals, which averaged 14 months in 2023 compared to 6–12 months in major regulatory markets (FDA: 6–10 months; EMA: 12–15 months). The National Pharmacovigilance Programme flagged over 12,000 adverse drug reaction reports in 2024.

UPSC angle: Drugs Act replacement bill, CDSCO approval timelines, pharmacovigilance, and medical devices separation are Mains GS-2/GS-3 content.

Jan Aushadhi Scheme — 16,912 Stores (June 2025)

The Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) reached 16,912 Jan Aushadhi Kendras (Janaushadhi stores) across India as of June 2025 — up from ~14,000 in 2024 — with a target of 25,000 stores by March 2027. The scheme makes quality generic medicines available at 50–90% below branded market price. Product range: 2,110 medicines + 315 surgical consumables (2025). Monthly sales exceed ₹125 crore. Cumulative savings to citizens since launch have crossed ₹30,000 crore (FY24 alone: ₹7,350 crore). Expansion to district hospitals, ESIC hospitals, and railway stations is increasing access for poor and tribal populations.

UPSC angle: PMBJP — 16,912 stores (June 2025), ₹30,000 crore cumulative savings, 2,110 medicines, target 25,000 stores by March 2027, and access for poor/tribal populations are Prelims data points; generic medicine policy and TRIPS flexibilities are Mains content.

PYQ Relevance

  • 2019 GS3 Prelims: CDSCO, DCGI, NPPA — frequently asked institution identification questions.
  • Pharma industry, API dependence on China, and compulsory licensing (TRIPS flexibilities) are recurring GS3 Mains themes. Prepare: "India's pharmaceutical industry faces the challenge of raw material dependence. Discuss the policy measures to address API import dependence on China."
  • Jan Aushadhi scheme and generic medicine policy have been asked as short-answer questions under governance/welfare schemes in GS2/GS3.
  • The Natco vs Bayer compulsory license (2012) and Section 3(d) of the Patents Act are standard Prelims and GS3 content on TRIPS flexibilities and public health.

Exam Strategy

Key numbers:

  • China's share in India's API imports: ~70% overall, up to 87% for antibiotics
  • PLI for Bulk Drugs outlay: Rs 6,940 crore
  • Jan Aushadhi Kendras: ~16,912 (June 2025); target 25,000 by March 2027
  • First compulsory license: March 9, 2012 (Natco vs Bayer, Nexavar)
  • Pharma exports: $30.47 billion FY25; $31 billion FY26 (Pharmexcil); target $65 billion by 2030
  • India's US generic market share: ~40–50% of US generic prescriptions by volume (highest for any single country)

Mains framing: India's pharma paradox = world's pharmacy for final products, but dependent on China for raw materials. PLI is the supply-side fix; Jan Aushadhi is the demand-side/access fix. Section 3(d) and compulsory licensing are the IP-flexibility tools protecting public health.

Link to Ujiyari.com for updates on PLI scheme progress, NLEM 2022 revisions, and the pharma sector in Union Budget 2025–26.

Key Terms

Biosimilars

  • Definition: A biosimilar is a biological medicine that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity and potency, despite minor variations in clinically inactive components. Because biologics are large, complex molecules produced in living systems, a biosimilar can only be "highly similar" to — never an identical copy of — its reference product.
  • Context: Biologics (such as monoclonal antibodies, insulin, vaccines and recombinant proteins) are far larger and more complex than conventional chemically-synthesised drugs, so they cannot be reproduced exactly the way a chemical generic copies a small-molecule drug. After a biologic's patent expires, manufacturers can develop biosimilars through an abbreviated pathway that relies on extensive comparability studies rather than full repeat clinical trials. The European Medicines Agency authorised the world's first biosimilar, Omnitrope (a somatropin/human growth hormone), in April 2006, and the US FDA approved its first biosimilar, Zarxio (filgrastim-sndz), in March 2015. India has emerged as a major biosimilars hub, with its first product launched in 2000 and a dedicated regulatory framework since 2012.
  • UPSC Relevance: This is a foundational GS3 science-and-technology and economy concept that underpins UPSC questions on biotechnology, intellectual property and the pharmaceutical sector ("pharmacy of the world"), affordable healthcare and indigenous innovation. For Prelims, candidates should be able to distinguish a biosimilar from a chemical generic and identify the regulators (CDSCO under the Ministry of Health, and the Department of Biotechnology's Review Committee on Genetic Manipulation). For Mains, it links to debates on access to affordable medicines, India's competitive edge in biopharma, and the IPR/patent-cliff dimension. No direct PYQ exists on this exact term, but it sits within the recurring biotechnology and drug-regulation theme.